TY - JOUR
AB - Sarcomas represent a heterogeneous group of mesenchymal malignancies arising at various locations in the soft tissue and bone. Though a rare disease, sarcoma affects ~200,000 patients worldwide every year. The prognosis of patients with sarcoma is poor, and targeted therapy options are limited; therefore, accurate diagnosis and classification are essential for effective treatment. Sarcoma samples were acquired from 199 patients, in which TP53 (39.70%, 79/199), CDKN2A (19.10%, 38/199), CDKN2B (15.08%, 30/199), KIT (14.07%, 28/199), ATRX (10.05%, 20/199) and RB1 (10.05%, 20/199) were identified as the most commonly mutated genes (>10% incidence). Among 64 soft‑tissue sarcomas that were unclassified by immunohistochemistry, 15 (23.44%, 15/64) were subsequently classified using next‑generation sequencing (NGS). For the most part, the sarcoma subtypes were evenly distributed between male and female patients, while a significant association with sex was detected in leiomyosarcomas. Statistical analysis showed that osteosarcoma, Ewing's sarcoma, gastrointestinal stromal tumors and liposarcoma were all significantly associated with the patient age, and that angiosarcoma was significantly associated with high tumor mutational burden. Furthermore, serially mutated genes associated with myxofibrosarcoma, gastrointestinal stromal tumor, osteosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma and Ewing's sarcoma were identified, as well as neurotrophic tropomyosin‑related kinase (NTRK) fusions of IRF2BP2‑NTRK1, MEF2A‑NTRK3 and ITFG1‑NTRK3. Collectively, the results of the present study suggest that NGS‑targeting provides potential new biomarkers for sarcoma diagnosis, and may guide more precise therapeutic strategies for patients with bone and soft‑tissue sarcomas.
AD - Department of Orthopedic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat Sen University, Guangzhou, Guangdong 510080, P.R. China
OrigiMed Co. Ltd., Shanghai 201114, P.R. China
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Department of Pathology, Peking University Third Hospital, Beijing 100191, P.R. China
AU - Xu,Libin
AU - Xie,Xianbiao
AU - Shi,Xiaoliang
AU - Zhang,Peng
AU - Liu,Angen
AU - Wang,Jian
AU - Zhang,Bo
DA - 2021/05/01
DO - 10.3892/ol.2021.12614
IS - 5
JO - Oncol Lett
KW - sarcoma
diagnosis
next‑generation sequencing
genomic profiling
tumor mutational burden
biomarker
PY - 2021
SN - 1792-1074
1792-1082
SP - 353
ST - Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma
T2 - Oncology Letters
TI - Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma
UR - https://doi.org/10.3892/ol.2021.12614
VL - 21
ER -